1057 HBM7008, a first-in-class bispecific antibody targeting both B7-H4 and 4–1BB, exhibits robust anti-tumor immunity and low toxicity through B7-H4-directed 4–1BB activation
- Resource Type
- Source
- Regular and Young Investigator Award Abstracts.
- Subject
- Language